CAMZYOS Extends Cardiac-Myosin Inhibition to Adolescents

Company Bristol Myers Squibb Event Type Regulatory Approval / Label Expansion Modality Small Molecule Cardiac Myosin Inhibitor Asset CAMZYOS (mavacamten) Target Cardiac Myosin Disease Area Obstructive Hypertrophic Cardiomyopathy (Pediatric) Summary FDA expanded CAMZYOS to symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at…